Material Agreements

HPS Corporate Lending Fund terminated Managing Dealer Agreement dated August 3, 2021 with Emerson Equity LLC with Emerson Equity LLC valued at Termination effective as of April 11, 2024. (effective 2024-04-11).

“the Fund provided notice for the termination of the managing dealer agreement dated as of August 3, 2021 by and between the Fund and Emerson Equity LLC, which termination shall be effective as of April 11, 2024.”

Climb Bio, Inc. entered into Securities Purchase Agreement with several accredited institutional investors valued at 31,238,282 shares of the Company’s common stock ... at a price of $3.84 per PIPE Share (effective 2024-04-10).

“On April 10, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several accredited institutional investors (the “PIPE Investors”), pursuant to which the Company agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 31,238,282 shares of the Company’s common stock (the “PIPE Shares”), at a price of $3.84 per PIPE Share (the “Private Placement”).”

Climb Bio, Inc. entered into Agreement and Plan of Merger and Reorganization with Tenet Medicines, Inc. (effective 2024-04-10).

“On April 10, 2024, Eliem Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Acquisition Agreement”) by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Transitory Subsidiary”), Tenet Medicines, Inc., a Delaware corporation (“Tenet”), and, solely in his capacity as company equityholder representative, Stephen Thomas.”

STERIS plc entered into Equity Purchase Agreement with HuFriedy Group Holding LLC valued at $787.5 million in cash, subject to customary adjustments, and up to $12.5 million in contingent paym (effective 2024-04-10).

“On April 10, 2024, STERIS Corporation (“Seller”), a wholly owned subsidiary of STERIS plc (“STERIS”), and certain affiliates, entered into an Equity Purchase Agreement (the “Purchase Agreement”) with HuFriedy Group Holding LLC (the “Purchaser”), an affiliate of Peak Rock Capital LLC.”

Canoo Inc. entered into Purchase Agreement with certain special purpose vehicles managed by entities affiliated with Mr. Tony Aquila valued at $10,000,000 (effective 2024-04-09).

“On April 9, 2024 (the “Agreement Date”), Canoo Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain special purpose vehicles managed by entities affiliated with Mr. Tony Aquila, the Company’s Chief Executive Officer and Executive Chair (collectively, the “Purchasers”), in connection with the issuance, sale and delivery by the Company of an aggregate of 10,000 of shares (the “Preferred Shares”) of the Company’s Series C Cumulative Perpetual Redeemable Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), which is convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pursuant to which the Company issued warrants (the “Warrants”) to purchase in the aggregate 4,473,272 shares of Common Stock, for a total aggregate purchase price of $10,000,000.”

Monroe Capital Income Plus Corp amended Credit Agreement with KeyBank National Association valued at $119.5 million of aggregate commitments to $194.5 million of aggregate commitments (effective 2024-04-09).

“On April 9, 2024, Monroe Capital Income Plus Corporation (the “Company”), increased the Facility Amount pursuant to the accordion feature of the Term Credit and Security Agreement, dated December 20, 2022 (as amended, the “Credit Agreement”), between MC Income Plus Financing SPV II LLC, a wholly-owned subsidiary of the Company as borrower (the “Borrower”), and the Company, as collateral manager, with KeyBank National Association, as administrative agent (the “Administrative Agent”) and lead arranger, the lenders from time to time party thereto, U.S. Bank Trust Company, National Association, as collateral agent and collateral administrator, and U.S. Bank National Association, as document custodian (the “Credit Facility”).”

Longeveron Inc. amended Warrant Amendment Agreement with a holder (the “Holder”) of existing warrants (effective 2024-04-08).

“the Company also entered into an agreement (the “Warrant Amendment Agreement”) with a holder (the “Holder”) of existing warrants to purchase shares of the Company’s Common Stock to, in consideration for the Holder’s participation in the Offering and purchase of securities in the Offering, and contingent upon the closing of the Offering and the Holder’s participation in the Offering, amend the Holder’s existing warrants to purchase up to (a) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 13, 2029 (the “Series A Warrants”) and (b) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 14, 2025 (the “Series B Warrants” and together with the Series A Warrants, the “Existing Warrants”) to (i) reduce the Exercise Price (as defined in the Existing Warrants) of the Existing Warrants to $2.35 per share and (ii) amend the expiration date of the Series A Wa”

Longeveron Inc. entered into engagement letter with H.C. Wainwright & Co., LLC valued at 7.0% of the aggregate gross proceeds (effective 2024-03-01).

“As compensation to H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to an engagement letter, dated as of March 1, 2024, as amended on April 3, 2024, and April 9, 2024, by and between the Company and the Placement Agent, pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering, the Company paid the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering, plus a management fee equal to 1.0% of the aggregate gross proceeds raised in the Offering and certain expenses incurred in connection with the Offering.”

Longeveron Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.20 million (effective 2024-04-08).

“Certain institutional investors purchasing securities as part of the Offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of April 8, 2024.”

ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).

“On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).”

Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).

“On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).”

FTAI Aviation Ltd. terminated 2025 Notes Indenture for 6.50% Senior Notes due 2025 with U.S. Bank Trust Company, National Association valued at Redemption of $650.0 million aggregate principal amount of 6.50% Senior Notes due 2025, deposit of $ (effective 2024-04-02).

“On April 2, 2024, under the indenture, dated as of September 18, 2018, between the Issuer and the Trustee (as supplemented from time to time, the “2025 Notes Indenture”), the Issuer issued a conditional notice of redemption for any and all of the Issuer’s $650.0 million outstanding aggregate principal amount of its 2025 Notes, less the aggregate principal amount of 2025 Notes validly tendered and accepted in the Issuer’s concurrent Tender Offer.”

FTAI Aviation Ltd. entered into Indenture for 7.000% Senior Notes due 2031 with U.S. Bank Trust Company, National Association valued at $700,000,000 7.000% Senior Notes due 2031 (effective 2024-04-11).

“On April 11, 2024, Fortress Transportation and Infrastructure Investors LLC (the “Issuer”) issued $700,000,000 of its 7.000% Senior Notes due 2031”

Empire State Realty Trust, Inc. entered into Purchase Agreement with the purchasers named therein valued at $225 million (effective 2024-04-10).

“On April 10, 2024, Empire State Realty Trust, Inc. (the “Company”) and Empire State Realty OP, L.P. (the “Operating Partnership”), the operating partnership subsidiary of the Company, entered into a Note Purchase Agreement with the purchasers named therein (the “Purchase Agreement”)”

CYPHERPUNK TECHNOLOGIES INC. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $40 million (effective 2024-04-10).

“On April 10, 2024, Leap Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers,” and each, a “Purchaser”) providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company expects to issue and sell to the Purchasers an aggregate of (a) 12,660,993 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per Share equal to $2.82, and (b) pre-funded warrants, in the form attached to the Securities Purchase Agreement as Exhibit B (the “Pre-Funded Warrants”), to purchase 1,523,404 shares of Common Stock (such shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”), at a purchase price per Pre-Funded Warrant equal to (i) $2.819 (which is equal to the price”

Orgenesis Inc. entered into Asset Purchase and Strategic Collaboration Agreement with Griffin Fund 3 BIDCO, Inc., ("Germfree") valued at aggregate purchase price of $8,340,000 (effective 2024-04-05).

“On April 5, 2024, Orgenesis Maryland LLC (“Orgenesis Maryland”), a wholly-owned subsidiary of Orgenesis Inc., entered into an Asset Purchase and Strategic Collaboration Agreement (the “Purchase Agreement”) with Griffin Fund 3 BIDCO, Inc., (“Germfree"), for the sale by Orgenesis Maryland of five Octomera Mobile Processing Units and Labs (“OMPULs”) to Germfree”

World Omni Auto Leasing LLC entered into Underwriting Agreement with BofA Securities, Inc., MUFG Securities Americas Inc., TD Securities (USA) LLC and Wells Fargo Securities, LLC valued at $874,710,000 aggregate principal balance of various classes of Asset-Backed Notes, Series 2024-A (effective 2024-04-09).

““Depositor”) entered into an Underwriting Agreement with BofA Securities, Inc., MUFG Securities Americas Inc., TD Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named therein (collectively, the”

INVO Fertility, Inc. entered into Purchase Agreement with FirstFire Global Opportunities Fund, LLC valued at $275,000 (effective 2024-04-05).

“On April 5, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with FirstFire Global Opportunities Fund, LLC (the “ Buyer ”), pursuant to which the Buyer agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $275,000.00”

Public Storage entered into Underwriting Agreement with Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC valued at $1.0 billion aggregate principal amount of senior notes (effective 2024-04-09).

“On April 9, 2024, Public Storage (the “Company”) and Public Storage Operating Company, a subsidiary of the Company (“PSOC”), entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC, as joint book-running managers of the several underwriters named therein (the “Underwriters”), for the sale of $1.0 billion aggregate principal amount of senior notes in two tranches (collectively, the “Notes”).”

AFS SENSUB CORP. entered into Underwriting Agreement with BNP Paribas Securities Corp., CIBC World Markets Corp., Lloyds Securities Inc., SG Americas Securities, LLC, Wells Fargo Securities, LLC, Goldman Sachs & Co. LLC, Great Pacific Securities, MUFG Securities Americas Inc. and Scotia Capital (USA) Inc. (effective 2024-04-04).

“pursuant to the Underwriting Agreement attached hereto as Exhibit 1.1 , dated as of April 4, 2024 (the “ Underwriting Agreement ”), among GM Financial, AFS SenSub and the Representative.”

Cineverse Corp. entered into Loan and Security Agreement with BondIt LLC valued at not to exceed $3,666,000 (effective 2024-04-05).

“On April 5, 2024, Cineverse Terrifier LLC (“T3 Borrower”), a wholly-owned subsidiary of Cineverse Corp. (the “Company”) entered into a Loan and Security Agreement with BondIt LLC (“T3 Lender”) and the Company, as a guarantor (the “T3 Loan Agreement”).”

UNIVERSAL BIOSENSORS INC entered into Underwriting Agreement with an underwriter valued at approximately A$10 million (effective 2024-04-11).

“On April 11, 2024, Universal Biosensors, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with an underwriter named in the Underwriting Agreement (the “Underwriter”), whereby the Company agreed to issue: (i) up to 66,666,667 shares of its common stock in the form of CHESS Depositary Interests (“CDIs”)”

Novo Integrated Sciences, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at $6,210,000 (effective 2024-04-05).

“On April 5, 2024, Novo Integrated Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Streeterville Capital, LLC (the “Holder”), pursuant to which the Company issued a secured convertible promissory note (the “Note”) with a maturity date of April 8, 2025 (the “Maturity Date”), in the principal sum of $6,210,000 (the “Principal Sum”).”

FUELCELL ENERGY INC amended Amendment No. 1 with Jefferies LLC, B. Riley Securities, Inc., Barclays Capital Inc., BMO Capital Markets Corp., BofA Securities, Inc., Canaccord Genuity LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Loop Capital Markets LLC valued at $300,000,000 (effective 2024-04-10).

“On April 10, 2024, FuelCell Energy, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Open Market Sale Agreement SM , dated July 12, 2022 (the “2022 Sales Agreement”), with Jefferies LLC, B. Riley Securities, Inc., Barclays Capital Inc., BMO Capital Markets Corp., BofA Securities, Inc., Canaccord Genuity LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Loop Capital Markets LLC (each, an “Agent” and together, the “Agents”)”

ARROW ELECTRONICS, INC. entered into First Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 (effective 2024-04-10).

“The Notes were issued pursuant to the indenture, dated as of March 1, 2024 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by the first supplemental indenture, dated as of April 10, 2024 (the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), between the Company and the Trustee.”

INVACARE HOLDINGS Corp amended Third Amendment to the Loan and Security Agreement with White Oak Commercial Finance, LLC (effective 2024-04-08).

“On April 8, 2024, Invacare Holdings Corporation (the “ Company ”) entered into the Third Amendment to the Loan and Security Agreement (the “ Third Amendment ”) by and among the Company, certain of the Company’s direct and indirect North American subsidiaries (the “ ABL Borrowers ”), certain other of the Company’s direct and indirect North American subsidiaries (together with the Company, the “ ABL Guarantors ”), Invacare International Holdings Corp. (“ Intermediate Holdings ”), each lender party thereto (collectively, the “ Lenders ”), and White Oak Commercial Finance, LLC, as administrative and as collateral agent (the “ Agent ”).”

Maison Solutions Inc. entered into Xu Guarantee with Sellers (effective 2024-04-08).

“Also on April 8, 2024, in connection with the execution of the Senior Secured Note Agreement, and pursuant to the Purchase Agreement, John Jun Xu, Chairman, Chief Executive Officer and controlling stockholder of the Company, and Grace Xu, spouse of John Jun Xu (together with John Jun Xu, the “Xu Guarantors”), entered into a guarantee (the “Xu Guarantee” and, together with the Purchaser Guarantee, the “Guarantees”) to and for the benefit of the Sellers, pursuant to which the Xu Guarantors unconditionally guarantee the payment by Lee Lee of the Principal Amount, as adjusted pursuant to the Secured Note and the faithful and prompt performance by Lee Lee of the conditions and covenants of the Secured Note.”

Maison Solutions Inc. entered into Purchaser Guarantee with Sellers (effective 2024-04-08).

“On April 8, 2024, in connection with the execution of the Senior Secured Note Agreement, and pursuant to the Purchase Agreement, AZLL entered into a guarantee (the “Purchaser Guarantee”) to and for the benefit of the Sellers, pursuant to which AZLL unconditionally guarantees the payment by Lee Lee of the Principal Amount, as adjusted pursuant to the Secured Note and the faithful and prompt performance by Lee Lee of the conditions and covenants of the Secured Note.”

Maison Solutions Inc. entered into Security Agreement with Sellers (effective 2024-04-08).

“On April 8, 2024, pursuant to the Purchase Agreement and the Senior Secured Note Agreement, Lee Lee and AZLL (collectively, the “Grantors”) entered into a security agreement (the “Security Agreement”) with the Sellers as holders of the Secured Note.”

Maison Solutions Inc. entered into Senior Secured Note Agreement with Sellers valued at approximately $15.2 million (effective 2024-04-08).

“On April 8, 2024, pursuant to the Purchase Agreement, Lee Lee and AZLL entered into a senior secured note agreement (the “Senior Secured Note Agreement”) with the Sellers, pursuant to which Lee Lee issued the Sellers a secured promissory note (the “Secured Note”) for an aggregate initial principal amount of approximately $15.2 million, subject to certain adjustments as set forth therein (the “Principal Amount”).”

Maison Solutions Inc. entered into Stock Purchase Agreement with Meng Truong and Paulina Truong valued at approximately $22.2 million (effective 2024-04-04).

“On April 4, 2024, AZLL, LLC (“Purchaser” or “AZLL”), an Arizona limited liability company and a wholly-owned subsidiary of Maison Solutions Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Meng Truong (“Meng Truong”) and Paulina Truong (“Paulina Truong” and, together with Meng Truong, the “Sellers”), pursuant to which Purchaser purchased 100% of the outstanding equity interests in Lee Lee Oriental Supermart, Inc. d/b/a Lee Lee Oriental Supermarket, Lee Lee International Supermarkets or Lee Lee (“Lee Lee”) from the Sellers (the “Transaction”).”

Blockchain Coinvestors Acquisition Corp. I entered into Business Combination Agreement with Linqto, Inc. valued at approximately $700 million (effective 2024-04-09).

“On April 9, 2024, Blockchain Coinvestors Acquisition Corp. I, a Cayman Islands exempted company (“ BCSA ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”), by and among BCSA, BCSA Merger Sub I, Inc., a Delaware corporation (“ Merger Sub ”), and Linqto, Inc., a Delaware corporation (“ Linqto ”).”

Tevogen Bio Holdings Inc. amended Amended and Restated Securities Purchase Agreement with an investor valued at aggregate purchase price of $6.0 million (effective 2024-03-27).

“On March 27, 2024, the Company and the Investor entered into an Amended and Restated Securities Purchase Agreement, pursuant to which the parties amended and restated the Original Agreement and the Investor agreed to purchase 600 shares of Series A-1 Preferred Stock of the Company for an aggregate purchase price of $6.0 million.”

Nuvation Bio Inc. entered into Warrant Agreement with Continental Stock Transfer & Trust Company (effective 2024-04-09).

“On April 9, 2024, in connection with the Acquisition (as defined below), Nuvation Bio Inc. (the “Company”) entered into the amended and restated warrant agreement (the “Warrant Agreement”) with Continental Stock Transfer & Trust Company, as warrant agent”

NEXTNRG, INC. entered into Exchange Agreement with Next (members of Next), CEO Michael Farkas as representative (effective 2023-08-10).

“On August 10, 2023, and on November 8, 2023, the Company, the members of Next (a limited liability company at the time of such filings) and the CEO (the managing member of Next at the time), as an individual and also as the representative of the members of Next, entered into an Exchange Agreement (the “Exchange Agreement”), pursuant to which the Company agreed to acquire from such members of Next 100% of the membership interests of Next in exchange for the issuance by the Company to the members of Next of shares of common stock, par value $0.0001 per share, of the Company.”

NEXTNRG, INC. entered into Note with NextNRG Holding Corp. (formerly Next Charging, LLC) (“Next”) valued at $165,000 (effective 2024-04-08).

“On April 8, 2024, EzFill Holdings, Inc. (the “Company”) and NextNRG Holding Corp. (formerly Next Charging, LLC) (“Next”) entered into a promissory note (the “Note”) for the sum of $165,000 (the “Loan”) to be used for the Company’s working capital needs.”

89bio, Inc. entered into Collaboration Agreement with BiBo Biopharma Engineering Co., Ltd. valued at $135 million (effective 2024-04-04).

“On April 4, 2024, 89bio, Inc., a Delaware corporation (the “Company”), entered into a collaboration agreement (the “Collaboration Agreement”) with BiBo Biopharma Engineering Co., Ltd., a company incorporated under the laws of the People’s Republic of China (“BiBo”), pursuant to which BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved (the “Production Facility”)”

Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).

“On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock”

Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).

“On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),”

Surgery Partners, Inc. terminated Existing Indentures (2027 Notes Indenture and 2025 Notes Indenture) with Wilmington Trust, National Association valued at Satisfaction and discharge of 10.000% Senior Notes due 2027 and 6.750% Senior Notes due 2025 (effective 2024-04-10).

“In connection with the issuance of the Notes, on April 10, 2024, the Issuer effected a satisfaction and discharge of those certain Indentures, dated as of April 11, 2019 (the “2027 Notes Indenture”), among the Issuer, the guarantors party thereto from time to time and the Trustee, governing the Issuer’s 10.000% Senior Notes due 2027 (the “2027 Notes”) and that certain Indenture, dated as of June 30, 2017 (the “2025 Notes Indenture” and together with the 2027 Notes Indenture, the “Existing Indentures”), among the Issuer, the guarantors party thereto from time to time and the Trustee, governing the Issuer’s 6.750% Senior Notes due 2025 (the “2025 Notes” and together with the 2027 Notes, the “Existing Notes”).”

Surgery Partners, Inc. entered into Indenture dated April 10, 2024 with Wilmington Trust, National Association valued at $800,000,000 7.250% senior unsecured notes due 2032 (effective 2024-04-10).

“On April 10, 2024, Surgery Center Holdings, Inc. (the “Issuer”), a wholly owned subsidiary of Surgery Partners, Inc. (the “Registrant”), completed the issuance and sale of $800.0 million in gross proceeds of the Issuer’s 7.250% senior unsecured notes due 2032 (the “Notes”).”

NeueHealth, Inc. amended Incremental Amendment No. 2 with NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P., New Enterprise Associates 15, L.P. valued at $30.0 million (effective 2024-04-08).

“On April 8, 2024, (i) NeueHealth, Inc. (the “Company”) and (ii) NEA 18 Venture Growth Equity, L.P. (“NEA 18”), New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P. (collectively, the “NEA Lenders”) entered into Incremental Amendment No. 2 (“Incremental Amendment No. 2”) to the Credit Agreement, dated as of August 4, 2023, between the Company and NEA 18 (as amended to date, and as amended by Incremental Amendment No. 2, the “Amended Credit Agreement”) to provide for a term loan commitment increase in an aggregate principal amount of $30.0 million (the “Commitment Increase”) by the NEA Lenders under the Amended Credit Agreement.”

Babcock & Wilcox Enterprises, Inc. entered into Sales Agreement with B. Riley Securities, Inc., Seaport Global Securities LLC, Craig-Hallum Capital Group LLC and Lake Street Capital Markets, LLC valued at up to $50,000,000 (effective 2024-04-10).

“On April 10, 2024, Babcock & Wilcox Enterprises, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc., Seaport Global Securities LLC, Craig-Hallum Capital Group LLC and Lake Street Capital Markets, LLC (the “Agents”), in connection with the offer and sale from time to time by the Company of shares of the Company’s common stock, having an aggregate offering price of up to $50,000,000 (the “Shares”) through the Agents.”

ALPINE IMMUNE SCIENCES, INC. entered into Agreement and Plan of Merger with Vertex Pharmaceuticals Incorporated valued at $65.00 per share in cash, aggregate termination fee of $173 million (effective 2024-04-10).

“On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).”

Global Net Lease, Inc. entered into Environmental Indemnity Agreement with Bank of Montreal, Société Générale Financial Corporation, Barclays Capital Real Estate Inc., KeyBank National Association valued at Indemnification against environmental losses (effective 2024-04-05).

“In connection with the entry into the Loan Agreement, on April 5, 2024, the OP entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.”

Global Net Lease, Inc. entered into Guaranty Agreement with Bank of Montreal, Société Générale Financial Corporation, Barclays Capital Real Estate Inc., KeyBank National Association valued at Guaranty of full repayment and indemnification (effective 2024-04-05).

“In connection with the entry into the Loan Agreement, on April 5, 2024, the OP entered into a Guaranty Agreement (the “Guaranty”) and an Environmental Indemnity Agreement (the “Environmental Indemnity”) for the benefit of the Lenders.”

Global Net Lease, Inc. entered into Commercial Mortgage-Backed Security Loan Agreement with Bank of Montreal, Société Générale Financial Corporation, Barclays Capital Real Estate Inc., KeyBank National Association valued at $237 million (effective 2024-04-05).

“On April 5, 2024, Global Net Lease, Inc. (the “Company”), through subsidiaries (collectively, the “Borrowers”) of its operating partnership, Global Net Lease Operating Partnership, L.P. (the “OP”), entered into a commercial mortgage-backed security Loan Agreement (the “Loan Agreement”), with (i) Bank of Montreal, (ii) Société Générale Financial Corporation, (iii) Barclays Capital Real Estate Inc. and (iv) KeyBank National Association (each individually, a “Lender,” and collectively, the “Lenders”), in the aggregate amount of $237 million (the “Loan”).”

AMC Global Media Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $875,000,000 aggregate principal amount (effective 2024-04-09).

“On April 9, 2024, AMC Networks completed an offering of $875,000,000 aggregate principal amount of its 10.25% Senior Secured Notes due 2029”

AMC Global Media Inc. amended Amendment No. 3 with Bank of America, N.A., JPMorgan Chase Bank, N.A. (effective 2024-04-09).

“On April 9, 2024, AMC Networks Inc. (“AMC Networks”) entered into Amendment No. 3 (“Amendment No. 3”) to the Second Amended and Restated Credit Agreement, dated as of July 28, 2017”

ZEVRA THERAPEUTICS, INC. terminated Note Purchase Agreement with Nantahala Capital Management, LLC (effective 2024-04-04).

“On April 4, 2024, in connection with the Debt Financing, the Company delivered to Nantahala Capital Management, LLC ("NCM"), certain of its affiliates and certain other parties (collectively with NCM, "Nantahala") a payoff letter in connection with its repayment of amounts outstanding under the Note Purchase Agreement with Nantahala (the "Note Purchase Agreement"), dated August 30, 2023.”